Abstract
COVID-19 has experienced an increase in 2,995,758 positive cases and 204,987 deaths, in distribution areas of more than 213 countries. This research using a systematic literature review, policy brief, and internet-based questionnaire with the aim of finding out the diagnosis and epidemiology of Coronavirus (COVID-19) outbreak in Indonesia. The cases in Indonesia have reached 9,771 and killed 784 people, possibly as many as 19 cases are asymptomatic but can be carriers of the virus. The diagnosis is carried out by rapid testing and using a polymerase chain reaction (PCR). Most of the patients diagnosed were aged 30-49 years (38.91%), the highest accompanying diseases were hypertension (34.85%), diabetes mellitus (25.76%), and cardiac disease (17.05%). The most signs and symptoms are that the patient has a cough, shortness of breath, and has a history of internal medicine and fever. Based on sex mostly experienced by men (58.94%) compared to women (41.06%), 60.4% of the community is still active outside the home. The Government of Indonesia is making efforts to reduce the COVID 19 outbreak by implementing a health protocol and a Large-scale Social Restrictions or “Pembatasan Sosial Berskala Besar (PSBB)†policy.
There is no Figure or data content available for this article
References
2. Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. https://doi.org/10.1056/NEJMoa2002032
3. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with SARSâ€CoVâ€2 infection: A single arm metaâ€analysis. J Med Virol. 2020;92(6):612-617. https://doi.org/10.1002/jmv.25735
4. Culp WC. Coronavirus Disease 2019. A A Pract. 2020;14(6):e01218. https://doi.org/10.1213/XAA.0000000000001218
5. Gugus Penanganan COVID-19. Peta Sebaran. Gugus Tugas Percepatan Penanganan COVID 19. https://covid19.go.id/peta-sebaran. Published 2020.
6. Wu A, Peng Y, Huang B, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325-328. https://doi.org/10.1016/j.chom.2020.02.001
7. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40(1):68-76. https://doi.org/10.1080/01652176.2020.1727993
8. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020;382(10):970-971. https://doi.org/10.1056/NEJMc2001468
9. Chan JF-W, Yuan S, Kok K, et al. A familial cluster of Pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523. https://doi.org/10.1016/S0140-6736(20)30154-9
10. Indonesia. COVID-19.; 2020.
11. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
12. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. https://doi.org/10.1001/jama.2020.1585
13. Maier HJ, Bickerton E, Britton P. Coronaviruses. Vol 1282. (Maier HJ, Bickerton E, Britton P, eds.). New York, NY: Springer New York; 2015. https://doi.org/10.1007/978-1-4939-2438-7
14. Li J, You Z, Wang Q, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 2020;22(2):80-85. https://doi.org/10.1016/j.micinf.2020.02.002
15. Yang J, Zheng Y, Gou X, et al. prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. https://doi.org/10.1016/j.ijid.2020.03.017
16. Dhama K, Patel SK, Pathak M, et al. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med Infect Dis. 2020;(March):101755. https://doi.org/10.1016/j.tmaid.2020.101755
17. Xu Y, Dong J, An W, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect. 2020;80(4):394-400. https://doi.org/10.1016/j.jinf.2020.02.017
18. Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from Coronavirus disease 2019 (COVID-19). Radiology. 2020;295(3):715-721. https://doi.org/10.1148/radiol.2020200370
19. Stang A, Standl F, Jöckel KH. Characteristics of COVID-19 pandemic and public health consequences. Herz. 2020;45(4):313-315. https://doi.org/10.1007/s00059-020-04932-0
20. Wang F-S, Zhang C. What to do next to control the 2019-nCoV epidemic? Lancet. 2020;395(10222):391-393. https://doi.org/10.1016/S0140-6736(20)30300-7
21. Biscayart C, Angeleri P, Lloveras S, Chaves T do SS, Schlagenhauf P, RodrÃguez-Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI). Travel Med Infect Dis. 2020;33(January):101567. https://doi.org/10.1016/j.tmaid.2020.101567
22. Song F, Shi N, Shan F, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology. 2020;295(1):210-217. https://doi.org/10.1148/radiol.2020200274
23. Kim JY, Choe PG, Oh Y, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci. 2020;35(5):1-4. https://doi.org/10.3346/jkms.2020.35.e61
24. WHO. (World Health Organization (WHO). Novel coronavirus (2019-nCoV). Situation report. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200428-sitrep-18-ncov.pdf?sfvrsn=fa644293_2).
How to Cite This
Article Metrics
Download Statistics
Downloads
Other Statistics
Copyright and Permissions
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.